Screener
BioMarin Pharmaceuticals BMRN Products excluding ALDURAZYME — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| United States | $371,074 | $272,554 | $614,018 | $514,248 |
| Europe | 297,498 | 243,138 | 516,334 | 472,716 |
| Latin America | 103,917 | 98,118 | 212,081 | 186,400 |
| Rest of world | 168,365 | 142,735 | 321,757 | 268,848 |
| Total net product revenues marketed by the Company | 940,854 | 756,545 | 1,664,190 | 1,442,212 |
| ALDURAZYME net product revenues marketed by Sanofi | 43,539 | 56,437 | 80,281 | 105,414 |
| Total net product revenues | $984,393 | $812,982 | $1,744,471 | $1,547,626 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's products excluding ALDURAZYME — total revenues?
- BioMarin Pharmaceuticals (BMRN) reported products excluding ALDURAZYME — total revenues of $940.85M in Q2 2026.
- How has BioMarin Pharmaceuticals's products excluding ALDURAZYME — total revenues changed year-over-year?
- BioMarin Pharmaceuticals's products excluding ALDURAZYME — total revenues increased by 24.4% year-over-year, from $756.55M to $940.85M.
- What is the long-term trend for BioMarin Pharmaceuticals's products excluding ALDURAZYME — total revenues?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's products excluding ALDURAZYME — total revenues has grown at a 15.5% compound annual growth rate (CAGR), from $1.66B to $2.96B.
- What does products excluding ALDURAZYME — total revenues mean?
- This metric represents the total revenue generated from the company's proprietary portfolio of rare-disease therapies, specifically excluding revenue derived from the Aldurazyme partnership. It serves as a primary indicator of the commercial performance and market adoption of the company's core, independently marketed product pipeline. This figure is critical for assessing the growth trajectory of the company's self-owned assets and its ability to scale high-value orphan drug therapies.
Ask your AI about BioMarin Pharmaceuticals's products excluding aldurazyme — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude